{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:17:15Z","timestamp":1784859435657,"version":"3.55.0"},"reference-count":32,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,1,12]]},"published-print":{"date-parts":[[2026,5]]},"DOI":"10.2967\/jnumed.125.270604","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:26:54Z","timestamp":1770913614000},"page":"700-708","source":"Crossref","is-referenced-by-count":2,"title":["Preclinical\n                    <sup>203\/212<\/sup>\n                    Pb-DOTA\u2013Based Pretargeted Radioimmunotherapy in Nude Mice Bearing Established Human Colorectal Cancer Xenografts"],"prefix":"10.2967","volume":"67","author":[{"given":"Brett A.","family":"Vaughn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren R.","family":"Veach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Burnes","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blesida","family":"Punzalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S.","family":"Rinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward K.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Fen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouathek","family":"Ouerfelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"St. Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kong V.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Cheal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026050105301240000_67.5.700.1","doi-asserted-by":"crossref","first-page":"1020188","DOI":"10.3389\/fmed.2022.1020188","article-title":"Development of radiopharmaceuticals for targeted alpha therapy: where do we stand?","volume":"9","author":"Pallares","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"2026050105301240000_67.5.700.2","doi-asserted-by":"crossref","unstructured":"Eychenne R Cherel M Haddad F Guerard F Gestin JF . Overview of the most promising radionuclides for targeted alpha therapy: the \u201chopeful eight.\u201d Pharmaceutics. 2021;13:906.","DOI":"10.3390\/pharmaceutics13060906"},{"key":"2026050105301240000_67.5.700.3","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00259-023-06529-1","article-title":"First-in-human SPECT\/CT imaging of [212Pb]Pb-VMT-alpha-NET in a patient with metastatic neuroendocrine tumor","volume":"51","author":"Michler","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026050105301240000_67.5.700.4","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00259-023-06559-9","article-title":"Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy","volume":"51","author":"Li","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026050105301240000_67.5.700.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266774"},{"key":"2026050105301240000_67.5.700.6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s41181-025-00362-7","article-title":"Pb in targeted radionuclide therapy: a review","volume":"10","author":"Scaffidi-Muta","year":"2025","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026050105301240000_67.5.700.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1524\/ract.1993.60.1.1","article-title":"The chemical fate of 212Bi-DOTA formed by \u03b2-decay of 212Pb(DOTA)2","volume":"60","author":"Mirzadeh","year":"1993","journal-title":"Radiochim Acta."},{"key":"2026050105301240000_67.5.700.8","doi-asserted-by":"publisher","DOI":"10.3934\/medsci.2015.3.228"},{"key":"2026050105301240000_67.5.700.9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01287"},{"key":"2026050105301240000_67.5.700.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262186"},{"key":"2026050105301240000_67.5.700.11","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.7150\/thno.48810","article-title":"Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors: safety at curative doses","volume":"10","author":"Cheal","year":"2020","journal-title":"Theranostics."},{"key":"2026050105301240000_67.5.700.12","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.9.3.465"},{"key":"2026050105301240000_67.5.700.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2330"},{"key":"2026050105301240000_67.5.700.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2010.08.013"},{"key":"2026050105301240000_67.5.700.15","doi-asserted-by":"crossref","unstructured":"Kumar K Magerst\u00e4dt M Gansow OA . Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta. J Chem Soc Chem Commun. 1989:145\u2013146.","DOI":"10.1039\/C39890000145"},{"key":"2026050105301240000_67.5.700.16","first-page":"528","article-title":"Mathematical modeling of in\u00a0vivo alpha particle generators and chelator stability","volume":"38","author":"Zaid","year":"2023","journal-title":"Cancer Biother Radiopharm."},{"key":"2026050105301240000_67.5.700.17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-015-3254-8","article-title":"Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825\/GPA33 IgG bispecific immunoconjugates","volume":"43","author":"Cheal","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026050105301240000_67.5.700.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267685"},{"key":"2026050105301240000_67.5.700.19","first-page":"P1294","article-title":"Pretargeted radioimmunotherapy with 212Pb-DOTA-based haptens in nude mice bearing established human-colorectal xenografts [abstract]","volume":"64(suppl 1)","author":"Vaughn","year":"2023","journal-title":"J Nucl Med."},{"key":"2026050105301240000_67.5.700.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268345"},{"key":"2026050105301240000_67.5.700.21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1021\/acs.bioconjchem.9b00736","article-title":"An N-acetylgalactosamino dendron-clearing agent for high-therapeutic-index DOTA-hapten pretargeted radioimmunotherapy","volume":"31","author":"Cheal","year":"2020","journal-title":"Bioconjug Chem."},{"key":"2026050105301240000_67.5.700.22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004110945"},{"key":"2026050105301240000_67.5.700.23","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-023-06494-9","article-title":"Structural modifications toward improved lead-203\/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors","volume":"51","author":"Lee","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026050105301240000_67.5.700.24","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1162546"},{"key":"2026050105301240000_67.5.700.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266388"},{"key":"2026050105301240000_67.5.700.26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jlcr.3825","article-title":"Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212Pb]Pb-NG001 for prostate cancer","volume":"63","author":"Stenberg","year":"2020","journal-title":"J Labelled Comp Radiopharm."},{"key":"2026050105301240000_67.5.700.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0433-x"},{"key":"2026050105301240000_67.5.700.28","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1021\/acs.bioconjchem.7b00612","article-title":"Metal-free cycloaddition chemistry driven pretargeted radioimmunotherapy using alpha-particle radiation","volume":"28","author":"Shah","year":"2017","journal-title":"Bioconjug Chem."},{"key":"2026050105301240000_67.5.700.29","first-page":"S56","article-title":"Preclinical evaluation of CEA-PRIT, a novel pretargeted alpha therapy regimen for treatment of CEA-positive tumours with Pb-212. [abstract]","volume":"46","author":"Frost","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026050105301240000_67.5.700.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2005.06.009"},{"key":"2026050105301240000_67.5.700.31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2150"},{"key":"2026050105301240000_67.5.700.32","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.3390\/molecules27185831","article-title":"Dosimetry of [212Pb]VMT01, a MC1R-targeted alpha therapeutic compound, and effect of free 208Tl on tissue absorbed doses","volume":"27","author":"Orcutt","year":"2022","journal-title":"Molecules."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:31:19Z","timestamp":1777638679000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.2967\/jnumed.125.270604"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270604","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}